Prof. Olivier Benveniste’s Inflammatory myopathies and innovative targeted therapies team at the Institute of Myology has produced a new classification of the different forms of myositis (rare inflammatory muscle diseases). Four new types of myositis taking into account the various clinical criteria of patients have now been defined. This research, involving teams from the Institute of Myology, Inserm, the Paris public hospitals system (AP-HP) and Sorbonne Université, was published...
Researchers from Inserm, CNRS and Sorbonne Université at the Paris-Seine Neuroscience laboratory1 in collaboration with Institut Pasteur2, New York University (NYU) and University of California Berkeley (UC Berkeley) have succeeded in controlling the activity of nicotine receptors in the brains of mice. To do this, they developed an optogenetic pharmacology strategy in which light is used to block the nicotine receptors, with the result being the possibility to control...
The adult brain has a very limited capacity for regeneration. However, researchers have updated the role of a key membrane molecule in the proliferation of stem cells in the adult mouse brain: Syndecan-1. CEA, Inserm and the Paris-Sud and Paris Diderot universities have joined forces to demonstrate that Syndecan-1, present in the membrane of the neural stem cells, permits their proliferation. Syndecan-1 therefore becomes a possible tracer of brain...
A study conducted by a group of researchers from Paris Diderot University, INSERM and the Institut Pasteur reveals the existence of a genetic factor influencing the function of the human thymus. The results of the study, part of the Laboratories of Excellence project Milieu Intérieur coordinated by the Institut Pasteur, are published in the journal Science Translational Medicine on September 5, 2018.
Teams of AP-HP, Inserm and Université Paris Sud, studied as part of an international research group, depressions called "subsyndromal" among young teenagers as they have a high risk to progress to depression in adolescence and later in adulthood.
Epidemics have no concept of borders! That is why, via Inserm, France is making a commitment to the health of European citizens by creating a European platform to intensify national responses to the challenges posed by vaccination. This European Joint Action on Vaccination (EU-JAV), coordinated by Inserm and backed by the French health ministry, was launched on September 4 with the participation of 19 other European countries.
Imagine that you are eating a Granny apple under a red parasol on the terrace of a public garden. The next day you eat another Granny apple at home in your kitchen, but soon afterwards find yourself ill. The next time you go back to the public garden, you avoid sitting under that red parasol. While there may not seem to be a link between the parasol and the...
Des chercheurs de l’Inserm et de l’Université Grenoble Alpes ont révélé un nouveau réseau cérébral qui relie la douleur ressentie dans la maladie de Parkinson à une région spécifique du cerveau. Ces travaux, paru dans la revue eLife, révèlent qu’un sous-ensemble de neurones situé dans une partie du cerveau appelée noyau sous-thalamique serait une cible potentielle pour soulager la douleur dans la maladie de Parkinson, ainsi que dans d’autres...
The digestive oncology teams from European Georges Pompidou Hospital, Cochin and Ambroise Paré AP-HP, and laboratory "Information Sciences and personalized medicine" of 1138 Unit Research Center Cordeliers INSERM and Paris-Descartes University, have developed an artificial intelligence system that predict therapeutic response to preoperative chemoradiotherapy in patients monitored for rectal cancer. The work, coordinated by Dr. Jean-Emmanuel Bibault of oncology radiotherapy European Hospital Georges Pompidou AP-HP, would propose a conservative treatment...
Inserm researchers at I-Stem – the Institute for Stem Cell Therapy and Exploration of Monogenic Diseases – report encouraging results with metformin, a known diabetes drug, for the symptomatic treatment of Steinert myotonic dystrophy. A phase II trial conducted in 40 patients at Henri-Mondor Hospital AP-HP has shown that, after 48 weeks of treatment at the highest dose, patients treated with metformin (versus placebo) gain in motor skills and recover...